A new collaboration aims to tackle the toughest challenges in IBD research by combining real-world data with AI-powered trial design to drive more personalized and successful treatments.

PhaseV has announced a strategic partnership with the Crohn’s & Colitis Foundation to accelerate research and therapy development for inflammatory bowel disease (IBD) – a condition affecting approximately 1 in 100 Americans.

The collaboration will integrate the Foundation’s IBD Plexus – the world’s most comprehensive IBD patient data and biosample repository – with PhaseV’s advanced AI and machine learning (ML) platform. The aim is to transform clinical trial design and execution for biopharma sponsors focused on IBD therapies.

“We are committed to breaking down barriers in clinical development to drive transformative progress for the IBD community,” said Angela Dobes, Senior Vice President of IBD Plexus. “By leveraging the unparalleled breadth of IBD Plexus’ data alongside PhaseV’s cutting-edge AI and machine learning platform, we aim to transform trial design and patient recruitment, expediting timelines and advancing more tailored solutions to improve outcomes for IBD patients.”

Designing effective clinical trials in IBD is particularly challenging due to patient heterogeneity – from differences in disease subtype, severity, and immune response to genetic background. Traditional fixed trial designs often fail to account for this complexity, leading to missed signals and delayed access to effective treatments.

By applying PhaseV’s AI/ML solutions to the IBD Plexus datasets, the partnership enables adaptive trial designs that can evolve in real time based on accumulating data. This approach supports more precise patient stratification, biomarker discovery, and the development of targeted therapies.

“IBD is a complex disease that demands new approaches to research and development,” said Raviv Pryluk, PhD, CEO and Co-founder of PhaseV. “We are proud to partner with the Crohn’s & Colitis Foundation, reflecting our commitment to addressing the most pressing challenges in IBD therapy development to deliver more effective treatments for patients.”

PhaseV’s platform has already helped over 30 pharma and biotech sponsors reduce trial costs by up to 50%, shorten timelines, and increase the likelihood of trial success. By applying these capabilities to IBD, the partners hope to accelerate access to new and more effective treatments.